(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
|
|
|
- ゆき しばもと
- 7 years ago
- Views:
Transcription
1
2 (1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA) (2) Draize (1) Ames in vitro in vivo (1) (2)...138
3 2-AA 9-AC ALP EMS DNCB ENNG OTC LD 50 NF 20-MC CPA MNPCE MCH MCHC PCE S.D. S.E N- -N - -N- ( ) 50% Micronucleated Polychromatic Erythrocytes Mean Corpuscular Hemoglobin Mean Corpuscular Hemoglobin Concentration Polychromatic Erythrocytes ( ) ( ) (+)-(S)-4-[1-(2,3-dimethylphenyl)ethyl]-1 H-imidazole monohydrochloride JAN dexmedetomidine hydrochloride (DEX) INN dexmedetomidine (R)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-i midazole
4 -1 (g/kg/) (g/kg/) : 5 mg/kg mg/kg : 10 mg/kg : 5 mg/kg mg/kg : 5 mg/kg : 2 mg/kg mg/kg : >2 mg/kg GLP ( ) -1 ( ) -2-3 ( ) -4-5 ( ) : < : <10 ( ) : < : <10 ( ) 10 6 Seg (2 ) ( ) ( ) Seg < ( ) Seg ( ) 8 16 ( ) g/kg/infusion ( ) ( ) ( ) g/kg/infusion 1.0 mg/animal -13 (6 ) ( ) 50g/animal -14 (10 ) ( ) 106
5 51500 g/plate ( ) Ames Test g/plate ( ) g/ml ( ) GLP ( ) g/ml S9 mix g/ml -18 ( ) in vitro g/ml -19 S9 mix g/ml ( ) g/kg ( ) NMRI 5.0 mg/kg ( ) -1 in vivo CD-1-21 mg/kg ( ) g/mL -22 g/ml ( ) g/mL in vitro -23 g/ml ( ) g/kg/ : 400 : 400 g/kg/ ( ) mg/kg 2 mg/kg 1 mg/kg g/kg/ 10g/kg/ g/kg/ 250g/kg/ 10g/kg/ 107
6 18g/kg/ 54g/kg/ 6g/kg/ 200g/kg/ 20g/kg/ 96g/kg/ 96g/kg/ 8g/kg/ 2g/kg/ ( ) Ames 5 mg/kg NMRI GLP CD-1 GLP 5 mg/kg L 28 PR 400 g/kg/ 108
7 0.120 mg/kg mg/kg 10 5 mg/kg NMRI 30 g mg/kg 5 5 mg/kg 5 mg/kg : mg/kg 10 mg/kg : 1 20 mg/kg : 1 SD mg/kg 5 5 mg/kg 5 5 mg/kg 5 mg/kg : 4 10 mg/kg : 5 20 mg/kg : 5 5 mg/kg : 4 10 mg/kg : 4 20 mg/kg : 5 109
8 mg/kg 14 ( -3) 2.0 mg/kg 1 1 ( ) mg/kg 2.0 mg/kg mg/kg 2.0 mg/kg mg/kg 2.0 mg/kg 1015kg mg/kg 0.1mL/kg mg/kg 1.0mg/kg 2.0mg/kg ( ) () ( ) ( ) () ( ) ( ) ( ) 2 mg/kg 110
9 1 10 SD g/kg/ g/kg/ 160g/kg/ 40g/kg/ g/kg/ 160g/kg/ 160g/kg/ MCH MCHC 10 g/kg/ 40g/kg/ ALP 160g/kg/ PT PTT 40g/kg/ 1) 40g/kg/ 160g/kg/ ALP ALP ALP 2 2) 160g/kg/ 40g/kg/ 3)-5) 111
10 10g/kg/ 10 /kg/ SD g 150 g 1 ml/kg (g/kg/) RBC Hb Ht Ht MCH MCHC Na + ALP ALP K +, Mg +, Na + ph ph ph ( ) ( ) ( ( ) ) <10g/kg/ Bonferonni t 1) Kaheinen, P.: Research Report , Farmos Group Ltd., Research Center 2) Hirsimaki, P. et al: Research Report , Farmos Group Ltd., Research Center 3) Kamibayashi, T. et al:anesthesiology 93: (2000) 4) Bloor, B.C. et al: Anesthesiology 77: (1992) 5) Schmeling W.T. et al: Anesthesiology 75: (1991) 112
11 g/ g/kg/ 250g/kg/ 50g/kg/ 50g/kg/ 250g/kg/ 10 ( ) 250g/kg/ g/kg/ OTC( ) 250g/kg/ GPT OTC GPT 1) 2),3) 50g/kg/ PAS (Intracytoplasmic eosinophilic inclusion bodies) 250g/kg/ 1 PAS 4)-7) 113
12 10g/kg/ 10g/kg/ kg kg 0.25 ml/kg (g/kg/) OTC OTC GPT ph ph * 10g/kg/ * OTC(Ornithine Transcarbamylase) 1) Amacher, D.E. et al: Food Chem Toxcol 36: (1998) 2) Sanhouri, A.A. et al: Br Vet. J. 146: (1990) 3) Yannai, S. et al: Arch Toxicol 54: (1983) 4) Ghadially, F.N.: Fourth Ed., Boston: Butterworth-Heinemann, pp , (1997) 5) Wills, E.J.: Ultrastructural Pathology 16: (1992) 6) Biava, C. et al: Am J Pathol 46: (1965) 7) Murti, G.S. et al: Am J Vet Res 26:63-67 (1965) 114
13 24 SD g/kg/ g/kg/ 54 / 18g/kg/ 18g/kg/ 6 g/kg/ 18 54g/kg/ 18g/kg/ 20 18g/kg/ 54g/kg/ 2 1), 2) 54g/kg/ g/kg/ 2 3) F1 18g/kg/ (F0) 18g/kg/ 6g/kg/ 54g/kg/ (F1) 18g/kg/ 6g/kg/ 1)Magness, R.R. et al : Am. J. Obstet. Gynecol , )Eisenach, J.C. et al : Am. J. Obstet. Gynecol. 160(2) , )Akatuka, K. et al : J. Toxicol. Sci.(Suppl 2)
14 ) SD 6~7 210 g 10~ g 1 ml/kg g/kg/ (%) 2) 100 (24/24) 91.7 (22/24) 100 (24/24) 100 (24/24) (%) 2) 100 (24/24) 81.8 (18/22) 95.8 (23/24) 95.8 (23/24) ,3,4) ,3,4) (%) ,2,4) (%) ,2,4) ,2,4) ,3,4) ( ) (g) 3,4) ** *** (100 ) (79 ) (77 ) (97 ) (%) 100 (12/12) 100 (8/8) 100 (13/13) 91.7 (11/12) () 4) , , , ** *** (%) (%) * *** (g) 4) *** *** (%) 90 (9/10) 100 (9/9) 100 (13/13) 92.3 (12/13) 1,3, (%) 1,3,4) F 2 4 (%) 2) (g) 4) g/kg/ 54g/kg/ 6g/kg/ (1) 1 2) Fisher 3)Bonferonni t 4) S.D. * p<0.05 ** p<0.01 *** p<
15 25 SD g/kg/ g/ / 200 g/kg/ 20g/kg/ 200g/kg/ g/kg/ 200g/kg/ g/kg/ Seg 2 20g/kg/ 2g/kg/ 200g/kg/ 20g/kg/ 200g/kg/ 20g/kg/ 117
16 SD 3 ( ) g 1 ml/kg (g/kg/) ) 1,3,4) ,3,4) ,3,4) (% *** 2,3,4) ** 2,3,4) ) )1) *** (g) 1,4) *** (g) 1,4) *** ( ) 1) g/kg/ 20g/kg/ 20g/kg/ 1) Bonferroni t 2) 2 Fisher 3) * p< 0.05,** p< 0.01, *** p< ) S.D. 118
17 12 Himalayan g/kg/ g/kg/ 60 24g/kg/ g/kg/ 24g/kg/ g/kg/ g/kg/ 6g/kg/ 6g/kg/ 96g/kg/ 96g/kg/ Himalayan kg ml/kg g/kg (g/kg/) ) 1,3,4) ,3,4) () 2) % ,3,4) ) hr hr ) (g) 1,4) (g) 1,4) ( ) 2) (%) <6g/kg/ 96g/kg/ 96g/kg/ 1)t 2)Fisher 3)1 4) S.D. 119
18 1 22 SD g/kg/ Seg Seg 2g/kg/ 32g/kg/ 8g/kg/ 8g/kg/ 32g/kg/ 16g/kg/ 4 32 g/kg/ 8g/kg/ 7 (16 ) 32g/kg/ 2 32g/kg/ 20 32g/kg/ 8g/kg/ 2g/kg/ 120
19 SD ~240 g 1 ml/kg g/kg/ ) (%) 100 (22/22) 95.5 (21/22) 100 (22/22) 100 (21/21) 4) 1,3,7) (%) ,3,7) (%) (g) ( ) ) (%) 100 (21/21) 100 (21/21) 100 (21/21) 100 (21/21) (%) 95.2 (20/21) 100 (21/21) 100 (21/21) 90.5 (19/21) 1,3,7) ,3,7) ,3,7) ,3,7) ,3,7) F 2 (g) 7) (g) 7) g/kg/ 2g/kg/ 2g/kg/ 1) t 2) 2 Fisher 3) 1 4) 1 5) 6) 7) S.D. * p<0.05 ** p<0.01 *** p<
20 g/kg 416g/kg g/kg 0.25g/kg 4g/kg 8g/kg 4g/kg 8 16g/kg SD 116g/kg g/kg SD 8 16g/kg/ 4 mg/kg/ (168 ) 2 ml/kg/ mg/kg ) g/kg 122
21 p0.05, (Mann-Whitney U ) g/kg ( -10) hr 5hr p0.05 (Dunnett ) 123
22 No. 1hr 5hr S702 S705 S777 2mL/kg/infusion S786 S789 S793 L776 L779 L780 L790 8g/kg/infusion L791 L796 H701 H769 H782 16g/kg/infusion H783 H784 H785 P700 P767 P770 4mg/kg/infusion P792 P794 P797 : : ++ :
23 6 ( kg) 3 mg/kg mg/kg g/kg (16 24 mg/kg) 2 Seevers (A) (B) (1) (%)100 AB A 3 1 No. (%) 0.5 ml/kg 0.25 ml/kg g/kg g/kg mg/kg 24 mg/kg ) ) Seevers, M.H. : J. Pharmacol. Exp. Ther. 56, ,
24 4 ( kg) 10 / g/kg/ 30 / g/kg g/kg 30 / g/kg/ g/kg g/kg * (1 )** (2 )** (g/kg) 125 or or 1.0 No or 3 2 or * 3 ** 1 No g/kg (2 ) 0.25g/kg No
25 PCA Draize Hartley ( g 6 /) 2 ml(t 0 : ) 1.0 mg/2 ml/animal (T 1 : ) 1.0 mg/2 ml/animal (T 2 )1 3 2 (6 ) ml (T 0 T 1 T 2 T 3 T 4 T 5 ) 45 T 3 T mg /ml/animal T mg/ml/animal 0.5% (T 4 ) (T 3 ) (T 5 ) T 0 T 1 1) 2) PCA / s.c. T 3 (0.1 mg/animal) 5) i.v. 06 (1.0 mg/animal) 3) s.c. T 4 (1.0 mg/animal) 6) i.v. 66 T 2 (1.0 mg/animal) 4) s.c. T 5 (0.1 mg/animal) 5) i.v. 06 1) 3 2 (6 ) 2) PCA 1/16 1/64 1/ ) (0.5 mg/ml)2ml # 4) (0.5 mg/ml)2 ml # 5) (0.1 mg/ml)1 ml 6) (1.0 mg/ml)1 ml # 127
26 Hartley ( g 6~10 /) (T 0 : ) 0.05(w/v)DNCB(T 1 : ) 0.05 # (T 2 ) 1 3 (10 ) (1 0.1 ml/animal ml/animal) 2 T DNCB T 0 T ml DNCB (T 1 ) (T 0 T 2 ) ( -14) / No. T 0 T 1 T 2 / / DNCB /DNCB / (24 48 ) (24 48 ) 4 0/6 3/6 0/10 # 128
27 Ames in vitro in vivo TA1535 TA1537 T1538 TA98 TA g/ 5000g/ g/ g/ g/plate 1) 5 5g/plate 6 ( -15) 1500g/ g/ WP2uvrA g/ g/ 7 ( -16) 11000g/plate 1) OECD Guideline for testing of chemicals No. 471: Bacterial reverse mutation test 129
28 / TA1535 TA1537 TA1538 TA98 TA100 (g/ ) S-9mix (-) S-9mix (+) ENNG IL IL IL IL IL IL AC 80.0 X X NF AA IL IL IL IL S.D. N=3 ENNG N- -N - -N- 9-AC 9- NF 2-2AA 2- IL X 130
29 WP2uvrA / (g/ ) S-9mix (-) S-9mix (+) ENNG AA ENNG N- -N - -N- S.D. N=3 2AA 2-131
30 L5178Y TK+/-TK-/- L5178Y S-9mix TK % 200g/mL 10150g/mL S-9mix 2 S-9mix S-9mix 40g/mL 20200g /ml S-9mix 40g/mL 22237/10 6 cells 1) ( -17) (g/ml) () 1 2 () S-9mix () S-9mix () DMSO EMS *** *** DMSO * MC *** *** EMS 20-MC cell *p0.05, ***p ) Mitchell I.deG. et al: Mutagenesis 5: (1990) 132
31 18 32 S-9 mix % 3 S-9mix (1 300g/mL 2 350g/mL 32 ) % ( -18) S-9mix S-9mix S-9mix(-)EMS( ) S-9mix(+)CPA( ) (g/ml) S-9mix g *** 18 () (%) g *** 1 + (g/ml) S-9mix g * 20.0*** () (%) g * 20.5*** + (g/ml) S-9mix g *** 18 () (%) g *** + (g/ml) S-9mix g *** () (%) g *** 2 + (g/ml) S-9mix g *** 32 () (%) g *** + (g/ml) S-9mix g * 37.5*** () (%) g * 38.0*** (g) (+g) ***p0.001, *p
32 S-9mix -18 S-9mix 1 168g/ml 488g/ml g/ml g/ml 3 19 C B1-19 S-9mix 3 1 S-9mix S-9mix (-) C S-9mix (+) B1 S-9mix () S-9mix () 19 S-9mix () 2 3 S-9mix () 100 * p0.05 (g/ml) (%) * + (g/ml) (%) * + (g/ml) (%) * + (g/ml) * (%) + 134
33 NMRI g/kg PCE/NCE 2000 PCE PCE MNPCE g/kg -20 PCE/NCE MNPCE 250g /kg NMRI 5 mg/kg GLP -1 GLP NMRI g ( 24 ) 40( /kg) PCE/NCE MNPCE (%) PCE/NCE ( /kg) 250( /kg) 40(mg/kg) ** ** ** MNPCE (%) MNPCE(Micronucleated Polychromatic Erytrocytes) MNPCE(%)=MNPCE /PCE 100 **p0.01 1) O brien, H. et al: Br J Haematol 51: (1982) 2) Asanami, S. et al.: Mutation Res. 393: (1997)
34 CD mg/kg % 1ml PCE/NEC MNPCE (%) 50 mg/kg PCE/NECMNPCE (%) PCE/NEC MNPCE (%) CD (m /kg) 2.5(m /kg) 5.0(m /kg) 50(mg/kg) PCE/NCE * MNPCE (%) ** 24 PCE/NCE MNPCE (%) PCE/NCE * MNPCE (%) ** 48 PCE/NCE MNPCE (%) MNPCE(Micronucleated Polychromatic Erytrocytes) MNPCE(%)=MNPCE /PCE 100 *p0.05, **p
35 5 SD g/mL( 0.1mL) 5 20 mg/ml g/mL g/mL 1000g/mL 1 10 SD 400g 1 5 ( g/ ml 0.1mL 5 20mg/mL 0.1mL 0.1mL (g/ml) 20mg/mL
36 g/mL in vitro ( ) ( ) 545 nm g/mL 3000g/mL 100% ( ng/mL*) *: DEX W97-249W97-245W97-246W99-302W J-DEX mL 100L nm (g/ml) (%) g/kg/ 10000g/kg g/kg 2000g/kg 1 PR g/kg g/kg g/kg 10000g/kg 400g/kg/ 138
37 kg g (1 :3 :3 ) 400, 2000, 10000g/kg/ g/kg/ 3 2 (g/kg/) ) 2) PR 1) 2) 2) 400g/kg/ 1) 2) 139
ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm
![ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm](/thumbs/85/92935308.jpg "ESL ()-methyl 3-{4-[2-hydroxy-3-(isopropylamino)pro poxy]phenyl} propanoate monohydrochloride H 3 C O O JAN( ) JAN( )esmolol hydrochloride r-inn( )esm")
1 186 186 (1) - 192 (2) (ISAintrinsic sympathomimetic activity) 199 (3) ( MSAmembrane stabilizing activity) 2 (4) 21 (5) 212 (6) 216 (7) 219 (8) 224 (9) (ASL-8123) - 229 (1) d-esl l-esl - 231 2 235 235
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
取扱説明書 [F-08D]
![取扱説明書 [F-08D]](/thumbs/48/23832237.jpg "取扱説明書 [F-08D]")
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 22 a c b d 23 24 a b c a b c d e f g a b j k l m n o p q r s t u v h i c d e w 25 d e f g h i j k l m n o p q r s
10 2 2 10 6.5 78 1 65 / 30 / - 2 -
- 1 - 10 2 2 10 6.5 78 1 65 / 30 / - 2 - 3 3 30 8 4 8 6 11 14 45 14 7 8 1-3 - 4 1 () 20 4 9 4 9 3 9 4 PR 4 3-4 - - 5 - PR 15 4 PR 7 8 4 9 10-6 - 9 10 9 10 4 9 10 3 9 10 9 9 9 10 PR 1-7 - PR - 8 - 30 100-9
グリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
取扱説明書 ［F-12C］
F-12C 11.7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 a bc b c d d a 15 a b cd e a b c d e 16 17 18 de a b 19 c d 20 a b a b c a d e k l m e b c d f g h i j p q r c d e f g h i j n o s 21 k l m n o p q r s a X
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
エディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
,977 t 157,977 t mg l mg l BOD 9398 % OH = cm 3 / sec 11 = cm 3 / sec OH = /
1 9625 2219 CAS 75569 1, 2-1, 2- H 2 C CH CH 3 C 3 H 6 O 58.08 1 99 % 1. 2 2, 3-112.13 2, 3 34.23-37 449 2.8-37 % 2 d 0 4 0.859 4 d 20 0.8304 2 2, 4 2.00 = 1 53.33 kpa 400 mmhg18 59.33 kpa 445 mmhg20 5
ケイセントラ_製品情報概要_H1-4_収載_新発売
DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1
140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11
C033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
エコリシン点眼液/眼軟膏インタビューフォーム
2011 11 4 871319 1mL 5mg 5mg15 1g 5mg 5mg15 JAN JAN Erythromycin LactobionateJAN Colistin Sodium MethanesulfonateJAN 1970 3 31 1970 8 1 1970 7 20 TEL0120-921-839 06-6321-7056 9 17 https://www.santen.co.jp/medical/admin/a300.jsp
温泉の化学 １
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
Contents 4 06 IP2 41 Thermo Scientific Nalgene Nalgene
Nalgene & Packaging plastic Bottles & Vials Contents 4 06 IP2 41 Thermo Scientific Nalgene 5 07 42 8 08 43 9 09 45 11 10 46 Nalgene 12 11 50 13 12 53 01 20 13 61 02 28 14 64 03 33 15 66 04 37 16 / 67 05
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
合併後の交付税について
(1) (2) 1 0.9 0.7 0.5 0.3 0.1 2 3 (1) (a), 4 (b) (a), (c) (a) 0.9 0.7 0.5 0.3 0.1 (b) (d),(e) (f) (g) (h) (a) (i) (g) (h) (j) (i) 5 (2) 6 (3) (A) (B) (A)+(B) n 1,000 1,000 2,000 n+1 970 970 1,940 3.0%
福岡大学人文論叢47-3
679 pp. 1 680 2 681 pp. 3 682 4 683 5 684 pp. 6 685 7 686 8 687 9 688 pp. b 10 689 11 690 12 691 13 692 pp. 14 693 15 694 a b 16 695 a b 17 696 a 18 697 B 19 698 A B B B A B B A A 20 699 pp. 21 700 pp.
本文／一般演題＿吉田
184 quality of lifeqol mmhg Hb gdl CA Uml Niveau Hb Hb gdl RCC CT MRI T 185 CT A B MRI A:T B:T Douglas red spot S ml RCC 186 A B mg CAUml S MRI A B 187 188 S mg Sampson JA. Intestinal adenomas of endometriosis
untitled
ORYZA CERAMIDE -PTPCDP8TP20CD -WSPWSP8 -LL0.8 -PCPC8PC20 -WSPCWSPC8 -LCLC0.8 Ver.13.0HS ORYZA CERAMIDE Ver.13.0HS 1. 2. 20 NMR 4 ( 1) 1 Ver.13.0HS HO CH 2 OH O O OH OH OH C CH CH H 2 NH C O R C H C H (CH
ver5.1 HS 1. ALPHA LIPOIC ACID () S S COOH HS 1. α - SH COOH - ( 1) CoA -( 2)- - --P80 (--WSP8-L1-WSPC8 -LC1) - 1
ORYZA OIL & FAT CHEMICAL CO., LTD. ALPHA LIPOIC ACID --P () --P80 () --WSP8 () --L1 () --PC () --PC80 () --WSPC8 () --LC1 () ver. 5.1HS ver5.1 HS 1. ALPHA LIPOIC ACID 16 3 31 0331009 - () 19 5 24 0524001
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
取扱説明書 ［F-02F］
F-02F 4. 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 a b c d a b c d a b cd 9 e a b c d e 20 2 22 ab a b 23 a b 24 c d e 25 26 o a b c p q r s t u v w d h i j k l e f g d m n a b c d e f g h i j k l m n x 27 o
1. 4cm 16 cm 4cm 20cm 18 cm L λ(x)=ax [kg/m] A x 4cm A 4cm 12 cm h h Y 0 a G 0.38h a b x r(x) x y = 1 h 0.38h G b h X x r(x) 1 S(x) = πr(x) 2 a,b, h,π
![1. 4cm 16 cm 4cm 20cm 18 cm L λ(x)=ax [kg/m] A x 4cm A 4cm 12 cm h h Y 0 a G 0.38h a b x r(x) x y = 1 h 0.38h G b h X x r(x) 1 S(x) = πr(x) 2 a,b, h,π](/thumbs/101/149329485.jpg "1. 4cm 16 cm 4cm 20cm 18 cm L λ(x)=ax [kg/m] A x 4cm A 4cm 12 cm h h Y 0 a G 0.38h a b x r(x) x y = 1 h 0.38h G b h X x r(x) 1 S(x) = πr(x) 2 a,b, h,π")
. 4cm 6 cm 4cm cm 8 cm λ()=a [kg/m] A 4cm A 4cm cm h h Y a G.38h a b () y = h.38h G b h X () S() = π() a,b, h,π V = ρ M = ρv G = M h S() 3 d a,b, h 4 G = 5 h a b a b = 6 ω() s v m θ() m v () θ() ω() dθ()
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
アクテムラインタビューフォーム
2009 2 6 876399 IF 1998 9 FAX 80mg 1 4mL 80mg 200mg 1 10mL200mg 400mg 1 20mL400mg JAN TocilizumabGenetical RecombinationJAN 200mg 80400mg 2007 9 10 2008 4 16 2007 12 21 2008 6 13 2005 6 13 2008 6 13 2009
1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
案内（最終2）.indd
1 2 3 4 5 6 7 8 9 Y01a K01a Q01a T01a N01a S01a Y02b - Y04b K02a Q02a T02a N02a S02a Y05b - Y07b K03a Q03a T03a N03a S03a A01r Y10a Y11a K04a K05a Q04a Q05a T04b - T06b T08a N04a N05a S04a S05a Y12b -
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)